GlassScriptPhysician profile
Russell Burlison
NPI 1073517975
$4,938.97
in general payments reported to CMS, 2019-2025
31 companies · $440 in 2025
The $440 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $338 · 2021: $1,114 · 2022: $1,047 · 2023: $1,015 · 2024: $311 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.64 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Exeltis, USA INC. | $403.36 | 2021-2025 | Slynd, Solosec |
| Pfizer INC. | $376.35 | 2019-2024 | |
| Amgen INC. | $330.35 | 2020-2023 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $314.10 | 2021-2023 | |
| Hologic Sales and Service, LLC | $303.15 | 2022-2025 | Myosure Tissue Removal Device, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $266.24 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $247.78 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $200.76 | 2019-2023 | Balcoltra |
| Evofem Biosciences, INC. | $160.97 | 2021-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $160.79 | 2020-2025 | Veozah |
| Lupin INC. | $145.16 | 2020-2021 | |
| Shield Therapeutics INC | $96.72 | 2022-2024 | Accrufer |
| Aspira Women'S Health INC | $87.80 | 2021-2022 | |
| Sage Therapeutics, LLC | $76.01 | 2021-2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $75.36 | 2019-2021 | |
| Daiichi Sankyo INC. | $61.38 | 2019-2021 | |
| Duchesnay USA Incorporated | $56.94 | 2019 | |
| Millicent US INC | $56.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Lilly USA, LLC | $46.60 | 2019 | |
| Organon LLC | $46.46 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $37.43 | 2019-2020 | |
| Scynexis, INC. | $36.30 | 2022 | |
| Medtronic, INC. | $34.64 | 2025 | Ligasure |
| Novo Nordisk INC | $31.95 | 2023-2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $25.50 | 2025 | Qelbree |
| Welch Allyn | $24.97 | 2021 | |
| Becton, Dickinson and Company | $21.98 | 2025 | Bd Onclarity |
| Myovant Sciences INC. | $19.36 | 2022 | |
| Smith+Nephew, INC. | $17.21 | 2025 | Pico |
| Amag Pharmaceuticals, INC. | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Burlison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.